Abstract
Proton pump inhibitors are often prescribed concomitantly with clopidogrel and aspirin to patients post-percutaneous coronary interventions and/or an acute coronary syndrome to mitigate the risk of potential gastrointestinal bleeding, associated primarily with clopidogrel use. Over the last several years, there have been data both supporting and refuting a clopidogrel-proton pump inhibitor interaction. This review critically considers the current evidence and provides practical recommendations to healthcare providers.
MeSH terms
-
Animals
-
Biotransformation / genetics
-
Clopidogrel
-
Cytochrome P-450 Enzyme System / genetics
-
Cytochrome P-450 Enzyme System / metabolism
-
Drug Interactions
-
Evidence-Based Medicine
-
Gastrointestinal Hemorrhage / chemically induced
-
Gastrointestinal Hemorrhage / prevention & control*
-
Genotype
-
Humans
-
Phenotype
-
Platelet Aggregation Inhibitors / adverse effects
-
Platelet Aggregation Inhibitors / pharmacokinetics
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Polymorphism, Genetic
-
Practice Guidelines as Topic
-
Proton Pump Inhibitors / adverse effects
-
Proton Pump Inhibitors / pharmacokinetics
-
Proton Pump Inhibitors / therapeutic use*
-
Risk Assessment
-
Risk Factors
-
Ticlopidine / adverse effects
-
Ticlopidine / analogs & derivatives*
-
Ticlopidine / pharmacokinetics
-
Ticlopidine / therapeutic use
Substances
-
Platelet Aggregation Inhibitors
-
Proton Pump Inhibitors
-
Cytochrome P-450 Enzyme System
-
Clopidogrel
-
Ticlopidine